Research Topics
Species | R E BullerSummaryAffiliation: University of Iowa Country: USA Publications
| Collaborators
|
Detail Information
Publications
The influence of microvessel density on ovarian carcinogenesisPamela J B Stone
Holden Comprehensive Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, 4630 John Carver Pavilion, Iowa City, IA 52242, USA
Gynecol Oncol 90:566-71. 2003..The rate of decline of CA 125 during the initial response to treatment cannot be predicted based on CD31 counts, confirming a complex relationship between tumor vascularity, metastasis, and response to treatment...- Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancerR E Buller
Department of Pharmacology, The University of Iowa Hospitals and Clinics, Iowa City 52242 1009, USA
J Natl Cancer Inst 91:339-46. 1999..This scenario could represent a previously unrecognized mechanism for development of hereditary cancers. We investigated whether such a mechanism might contribute to the development of hereditary ovarian cancers... - Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500Richard E Buller
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1009, USA
Cancer Gene Ther 9:567-72. 2002..The purpose of the present investigation was to evaluate the long-term follow-up of these heavily pretreated patients subsequent to SCH 58500 dosing... - A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancerRichard E Buller
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1009, USA
Cancer Gene Ther 9:553-66. 2002..p.) alone and sequentially in combination with platinum-based chemotherapy, of patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer containing aberrant or mutant p53... - Failure of BRCA1 dysfunction to alter ovarian cancer survivalRichard E Buller
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospital and Clinic, Iowa City 52242 1009, USA
Clin Cancer Res 8:1196-202. 2002..Many factors modify ovarian cancer survival. There are conflicting reports regarding survival of individuals with hereditary BRCA1-related ovarian cancer. None have controlled for other mechanisms of BRCA1 silencing in the control cohort... - The p53 mutational spectrum associated with BRCA1 mutant ovarian cancerR E Buller
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1009, USA
Clin Cancer Res 7:831-8. 2001..Data from murine models and human BRCA1-related hereditary breast cancers suggest that both unique and specific BRCA1-associated p53 mutations may be found in BRCA1-related ovarian cancers... - p53 Mutations and microsatellite instability in ovarian cancer: Yin and yangR E Buller
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, Iowa City, 52242-1009, USA
Am J Obstet Gynecol 184:891-902; discussion 902-3. 2001..04). CONCLUSIONS: Microsatellite instability is a relatively common event in ovarian cancer and is dependent on marker selection. The p53 frameshift mutations do not appear to occur as a consequence of genomic instability... 
Cyclosporin A reverses chemoresistance in patients with gynecologic malignanciesA K Sood
Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA
Neoplasia 1:118-22. 1999..Cyclosporin A is well tolerated and has significant potential for reversal of chemoresistance in heavily pretreated patients with ovarian and uterine malignancies...- Distant metastases in ovarian cancer: association with p53 mutationsA K Sood
Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA
Clin Cancer Res 5:2485-90. 1999..These findings need to be carefully considered when choosing between regional versus systemic treatment modalities... - Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP)J P Geisler
Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
Hum Mutat 18:337-44. 2001..9%. The concordance rate for the two screening tests was 88.9%. Only SSCP can detect missense mutations. PTT is a superior screening test for truncating BRCA1 mutations that are expected to be of clinical significance... - Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinomaJ P Geisler
Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
Gynecol Oncol 83:501-3. 2001..001). CONCLUSION: Patients with UPSC have an increased risk of development of breast cancer as compared to patients with endometrioid adenocarcinoma of the uterus... - Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancerS K Lutgendorf
University of Iowa, Department of Psychology, Iowa City, Iowa 52242, USA
Cancer 89:1402-11. 2000..Quality of life (QOL) and mood were investigated among women who had received intensive chemotherapy for at least 1 year for advanced gynecologic cancers. Relationships of coping styles to QOL and mood in these patients also were examined... 
BRCA2 alteration is important in clear cell carcinoma of the ovaryM J Goodheart
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
Clin Genet 76:161-7. 2009..5%, compared to only 40% for those patients without a BRCA2 alteration (p = 0.39). Alterations in BRCA2 gene sequence, copy number, or expression are extremely common in CCC and may contribute to a paradoxical better clinical outcome...- Computed tomography in endometrial carcinomaJ P Connor
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
Obstet Gynecol 95:692-6. 2000..To determine the value of computed tomography (CT) scans for preoperatively detecting extrauterine-nodal disease and postoperative recurrent disease in patients with endometrial cancer... - Cervical cancer diagnosed shortly after pregnancy: prognostic variables and delivery routesA K Sood
Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
Obstet Gynecol 95:832-8. 2000..To compare the prognoses of women diagnosed with cervical cancer during pregnancy with the prognoses of those diagnosed within 6 months after delivery and to assess the effect of vaginal delivery on recurrence risk and prognosis... - Ovarian function after surgical treatment for cervical cancerT E Buekers
Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
Gynecol Oncol 80:85-8. 2001..The addition of UO or OT to this treatment reduces ovarian function appreciably. The addition of radiation therapy after OT dramatically shortens ovarian function... - Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancerA K Sood
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Holden Cancer Center, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242 1109, USA
Cancer Res 61:4371-4. 2001..MSI-H occurs in approximately 12% of invasive ovarian tumors. For optimal detection of microsatellite instability in ovarian cancer, an additional marker (NME1) may be required, along with the five recommended by the NCI... - Malignant mixed mullerian tumor of the ovary and bilateral breast cancer: an argument for BRCA3, or a coincidental cluster of unconnected cancers?B A Burns
Division of Gynecologic Oncology, Holden Comprehensive Cancer Center, Department of Pathology, University of Iowa, Iowa City, IA 52242, USA
Gynecol Oncol 91:426-8. 2003..Malignant mixed mullerian tumors (MMMTs) of the ovary are a rare, aggressive subtype of ovarian cancer without a clear relationship to familial breast-ovarian cancer syndromes... - The role of p53 mutation in BRCA1-associated ovarian cancerS L Rose
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
Minerva Ginecol 54:201-9. 2002..This review explores the evidence for BRCA1 and p53 interplay, and outlines the crucial role p53 may play in BRCA1-related ovarian cancer... - Molecular determinants of ovarian cancer plasticityA K Sood
Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 4630 JCP, 200 Hawkins Dr, Iowa City, IA 52242 1109, USA
Am J Pathol 158:1279-88. 2001..These results may offer new insights and molecular markers for consideration in ovarian cancer diagnosis and treatment strategies based on molecular vascular mimicry by aggressive tumor cells... - Tunneled central venous catheters in a gynecologic oncology service: operative and short-term complicationsJ P Geisler
Division of Gynecologic Oncology, Indiana Women s Oncology, St Vincent Hospitals, Indianapolis, IN, USA
Eur J Gynaecol Oncol 29:141-3. 2008..To determine the difference in the immediate complication rate between placement of long-term central venous catheters (LTCVCs) by the percutaneous versus jugular venous cutdown method... - Quality of life and mood in women with gynecologic cancer: a one year prospective studySusan K Lutgendorf
Department of Psychology, University of Iowa, Iowa City, IA 52242, USA
Cancer 94:131-40. 2002..Quality of life (QOL) and mood were prospectively investigated during the first year of treatment among women with gynecologic cancers. Relationships of coping styles to QOL and mood were examined... - The impact of p53 protein core domain structural alteration on ovarian cancer survivalStephen L Rose
The Holden Comprehensive Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA
Clin Cancer Res 9:4139-44. 2003..By evaluating ovarian cancer survival based upon a structure function analysis of the p53 protein, we tested the hypothesis that not all missense mutations are equivalent... - Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinomaJohn P Geisler
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
Cancer 98:2199-206. 2003..The purpose of the current study was to determine the relation between MSI of ovarian carcinoma and MMR gene expression, hMLH1 and hMSH2 hypermethylation, and hMLH1 and hMSH2 null mutations... - Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trialAnil K Sood
Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 10:6080-5. 2004..The purpose is to investigate the safety and efficacy of i.p. topotecan and oral etoposide as salvage treatment for patients with platinum-resistant ovarian or primary peritoneal cancer... - The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancerMichael J Goodheart
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa Hospital and Clinics, Iowa City, Iowa, USA
Clin Cancer Res 11:3733-42. 2005..Multiple angiogenic factors may influence tumor progression and metastasis. Several are modified by the p53 gene. We sought to identify molecular markers for high-risk stage I epithelial ovarian cancers... - Serum CA 125 is an independent prognostic factor in cervical adenocarcinomaDavid P Bender
Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, USA
Am J Obstet Gynecol 189:113-7. 2003..001). CONCLUSION: Serum CA 125 is an independent prognostic marker for patients with cervical adenocarcinoma... - Vascular endothelial growth factor and social support in patients with ovarian carcinomaSusan K Lutgendorf
Department of Psychology, University of Iowa, Iowa City, Iowa 52242, USA
Cancer 95:808-15. 2002..This study examined relationships of social support and depressive symptoms with VEGF levels in preoperative patients with ovarian carcinoma... - Frequency of BRCA1 dysfunction in ovarian cancerJohn P Geisler
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City 52242, USA
J Natl Cancer Inst 94:61-7. 2002..The use of LOH, rather than a family history of ovarian cancer, as a first step in a screening strategy, followed by protein truncation testing, appears to increase the chance of identifying tumors with BRCA1 dysfunction... - Ovarian cancer p53 mutation is associated with tumor microvessel densityMichael J Goodheart
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
Gynecol Oncol 86:85-90. 2002..It also suggests validity to targeting p53 alterations with gene replacement as well as the use of antiangiogenesis agents as novel molecular-based therapeutics for ovarian cancer... - Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancerBrian C Cooper
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, Iowa City 52242, USA
Obstet Gynecol 100:59-64. 2002..CONCLUSION:Preoperative CA 125 is an independent risk factor for death due to disease in ovarian cancer, but not a reliable predictor of optimal cytoreduction... - Inactivation of BRCA1 and BRCA2 in ovarian cancerJeffrey L Hilton
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Holden Comprehensive Cancer Center, Iowa City, IA, USA
J Natl Cancer Inst 94:1396-406. 2002..Our goal was to characterize BRCA2 mutations and mRNA expression in a group of ovarian tumors previously evaluated for BRCA1 mutations and mRNA expression... - Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancerBrian C Cooper
Division of Gynecologic Oncology, Departments of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
Clin Cancer Res 8:3193-7. 2002..004) were significant. CONCLUSIONS: Preoperative VEGF levels may be useful in differentiating benign adnexal masses from malignancy. Preoperative VEGF levels >380 pg/ml are an independent risk factor for death because of disease... - p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinomaAnil K Sood
Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 440, Houston, TX 77030 USA
Cancer Biol Ther 1:511-7. 2002..03). Ovarian cancers with a p53 null mutation are more likely to lack telomerase activity. This may have implications for therapeutic approaches based on telomerase... - p21 expression predicts outcome in p53-null ovarian carcinomaStephen L Rose
Holden Comprehensive Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA
Clin Cancer Res 9:1028-32. 2003..A dual role for p21 activity, dependent on levels of expression, appears to explain these paradoxical results and is consistent with a complex model for regulation of p21... - Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal disseminationAnalisa Difeo
Department of Human Genetics, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, New York 10029, USA
Clin Cancer Res 12:3730-9. 2006..We investigated the role of the KLF6 tumor suppressor gene and its alternatively spliced isoform KLF6-SV1 in epithelial ovarian cancer (EOC)... - Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyPeter G Rose
Division of Gynecologic Oncology, Case Western Reserve University, University Hospitals of Cleveland, OH 44106, USA
Gynecol Oncol 89:267-70. 2003..To evaluate prolonged oral etoposide in nonsquamous cell carcinoma of the cervix, the current phase II trial was conducted...